Serum Level of Fibroblast Growth Factor 21 in Type 2 Diabetic Patients with and without Metabolic Syndrome

2015 ◽  
Vol 15 (2) ◽  
pp. 80-86 ◽  
Author(s):  
Azam Shafaei ◽  
Masoud Khoshnia ◽  
Abdoljalal Marjani
Keyword(s):  
Metabolic Syndrome ◽  
Growth Factor ◽  
Serum Level ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

2020 ◽  
Author(s):  
Wangshu Liu ◽  
Tianli Xu ◽  
Mengjie Tang ◽  
Xue-Qin Wang ◽  
Jianbin Su ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Fibroblast Growth Factor 19 ◽  
Type 2 Diabetic

Abstract BackgroundWe aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients.MethodsSerum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated.ResultsT2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP (p for trend < 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level (p < 0.05). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant (p < 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) (p < 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p < 0.01).ConclusionsSerum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.

scholarly journals Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

2009 ◽  
Vol 161 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Ke Li ◽  
Ling Li ◽  
Mengliu Yang ◽  
Haihong Zong ◽  
Hua Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Fasting Plasma

ObjectiveFibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM).Design and methodsThirty patients with new-onset T2DM (nT2DM), 34 type 2 diabetic patients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed.ResultsFasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81±0.64 vs 1.87±0.63 vs 1.52±0.61 μg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59±0.63 vs 1.87±0.64 μ/l, P<0.05). In all diabetic patients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels.ConclusionsIn pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.

scholarly journals Fibroblast Growth Factor 21 Predicts the Metabolic Syndrome and Type 2 Diabetes in Caucasians

Diabetes Care ◽  
2012 ◽  
Vol 36 (1) ◽  
pp. 145-149 ◽  
Author(s):  
T. Bobbert ◽  
F. Schwarz ◽  
A. Fischer-Rosinsky ◽  
A. F. H. Pfeiffer ◽  
M. Mohlig ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
The Metabolic Syndrome

Fibroblast growth factor 21 as a predictor of early stage diabetic nephropathy in type 2 diabetic mellitus

2019 ◽  
Vol 22 (07) ◽  
pp. 01-07
Author(s):  
Samah Naji ◽  
Kareem Ghali ◽  
Najah Hadi ◽  
Maysaa Ali Abdul khaleq ◽  
Mohammed Abdelhussain
Keyword(s):  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Early Stage ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Diabetic Mellitus ◽  
Type 2 Diabetic Mellitus ◽  
Type 2 Diabetic

scholarly journals Serum Progranulin Levels in Type 2 Diabetic Patients with Metabolic Syndrome

2016 ◽  
Vol 54 (4) ◽  
pp. 211-216 ◽  
Author(s):  
Azam Shafaei ◽  
Abdoljalal Marjani ◽  
Masoud Khoshnia
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Serum Level ◽  
Hdl Cholesterol ◽  
Diabetic Patients ◽  
Control Groups ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract Introduction. The role of progranulin in individuals with metabolic syndrome is not exactly clear.We aimed to assess the serum level of progranulin in type 2 diabetic patients with and without metabolic syndrome and compare them with healthy controls. Methods. The study included 60 patients with type 2 diabetes and 30 healthy individuals as control groups. Biochemical parameters and progranulin levels were determined. Results. Subjects with metabolic syndrome showed significantly higher levels of triglyceride, waist circumference, BMI, systolic and diastolic blood pressure than subjects without metabolic syndrome and the control groups, while HDL-cholesterol level was significantly lower in subjects with metabolic syndrome. Fasting blood sugar was significantly higher in type 2 diabetic patients than in the control groups. Serum level of progranulin was slightly increased in subjects with metabolic syndrome. Serum progranulin level had no significant relationship with metabolic syndrome components. Conclusions. Serum progranulin was also not dependent on cardiometabolic risk factors for subjects with metabolic syndrome, but it could be considered for the management of type 2 diabetes mellitus. Further studies are recommended to explain the effect of progranulin on the pathogenesis of metabolic risk factors.

Serum level of insulin-like growth factor-I in type 2 diabetic patients: impact of obesity

2019 ◽  
Vol 39 (1) ◽  
Author(s):  
Shereen M. Aleidi ◽  
Eman Shayeb ◽  
Jameel Bzour ◽  
Eman Y. Abu-rish ◽  
Mohammad Hudaib ◽  
...  
Keyword(s):  
Growth Factor ◽  
Serum Level ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Factor I ◽  
Significant Difference ◽  
Igf I ◽  
Type 2 Diabetic

Abstract Background Insulin-like growth factor-I (IGF-I) is homologous to proinsulin and possesses glucose reducing activity. The association between the level of IGF-I and diabetes has been highlighted. However, this association is controversial due to the influence of different factors including obesity. The aim of the study was to evaluate serum level of IGF-I in type 2 diabetic patients compared to control subjects. Materials and methods A cross-sectional study involving 100 participants was conducted. Serum levels of IGF-I were measured using enzyme-linked immunosorbent assay (ELISA) and the fasting plasma glucose (FPG) levels were measured using the glucose oxidase method. Results IGF-I levels in the diabetic patients were significantly lower than in non-diabetic control subjects (105.13 ± 6.34 vs. 159.96 ± 9.62 ng/mL, p < 0.0001). Among the diabetic group, there was no significant difference in IGF-I levels between obese diabetic patients and non-obese diabetic patients, p = 0.18. Similarly, among the non-diabetic group, a non-significant difference was found in IGF-I levels between obese non-diabetic and non-obese non-diabetic subjects, p = 0.156. However, among the obese group, obese diabetic patients had significantly lower IGF-I serum levels compared to obese non-diabetic subjects (112.07 ± 7.97 vs. 147.07 ± 13.05 ng/mL, p = 0.02). Furthermore, among the non-obese group, the non-obese diabetic patients had significantly lower IGF-I serum levels compared to the non-obese non-diabetic subjects (91.66 ± 9.93 vs. 171.86 ± 13.86 ng/mL, p < 0.0001). No significant associations were observed between IGF-I level and any of the age, gender, body mass index (BMI), FPG levels, or the duration of diabetes. Conclusions Type 2 diabetes mellitus is associated with lower levels of IGF-I regardless to the presence or absence of obesity.

scholarly journals Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice

Endocrinology ◽  
2013 ◽  
Vol 154 (9) ◽  
pp. 3366-3376 ◽  
Author(s):  
H. W. Kim ◽  
J. E. Lee ◽  
J. J. Cha ◽  
Y. Y. Hyun ◽  
J. E. Kim ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Renal Injury ◽  
Mesangial Cells ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Type 2 Diabetic

Despite the emerging importance of fibroblast growth factor 21 (FGF21) as a metabolic hormone regulating energy balance, its direct effects on renal function remain unexplored. FGF21 was injected ip daily for 12 weeks into db/db mice. Compared with control vehicle injection, FGF21 treatment significantly improved lipid profiles and insulin resistance and resulted in significantly higher serum adiponectin levels. In contrast, serum insulin and 8-isoprostane levels were significantly decreased. Interestingly, FGF21 and its receptor components in the kidneys were found to be significantly up-regulated in db/db mice, which suggests an FGF21-resistant state. FGF21 treatment significantly down-regulated FGF21 receptor components and activated ERK phosphorylation. FGF21 administration also markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic molecule synthesis. Furthermore, FGF21 improved renal lipid metabolism and oxidative stress injury. In cultured renal cells, FGF21 was mainly expressed in mesangial cells, and knockdown of FGF21 expression by stealth small interfering RNA further aggravated high-glucose-induced profibrotic cytokine synthesis in mesangial cells. Our results suggest that FGF21 improves insulin resistance and protects against renal injury through both improvement of systemic metabolic alterations and antifibrotic effects in type 2 diabetic nephropathy. Targeting FGF21 could therefore provide a potential candidate approach for a therapeutic strategy in type 2 diabetic nephropathy.

Sign in / Sign up

Export Citation Format

Share Document